SILVER SPRING, Md., June 20, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, was interviewed by Stock News Now (SNN) at the 5th Annual Marcum MicroCap Conference in New York City. The SNNLive video interview can be viewed by clicking on the following link:

During his interview, Mr. Waggoner describes how PharmaCyte plans to use its live cell encapsulation technology, known as Cell-in-a-Box®, for the development of treatments for locally advanced, inoperable pancreatic cancer and for Type 1 and insulin-dependent Type 2 diabetes. Mr. Waggoner also discusses the mechanism of action PharmaCyte uses to treat cancerous tumors and talks about PharmaCyte’s plans to begin a Phase 2b clinical trial in patients with locally advanced, inoperable pancreatic cancer. That trial is planned to start in Q4 2016.

In discussing PharmaCyte’s efforts to develop a treatment for diabetes, Mr. Waggoner talks about the preclinical studies that are being conducted concurrently by several renowned experts in the field of diabetes in various countries around the globe. All of these experts are members of PharmaCyte’s International Diabetes Consortium. Mr. Waggoner also explains that by conducting their studies as part of a consortium, rather than sequentially, the overall treatment development timeline has been shortened considerably. This will allow PharmaCyte to potentially begin a clinical trial in diabetes as early as late 2017.

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements. 

More information about PharmaCyte can be found at It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856

Primary Logo

Source: PharmaCyte Biotech, Inc.